Lexaria Bioscience Corp. (NASDAQ: LEXX) Celebrates
Post# of 420
(Total Views: 238)
Posted On: 01/12/2022 4:36:35 PM
Lexaria Bioscience Corp. (NASDAQ: LEXX) Celebrates Productive Year for Blood Pressure Drug Solution with Eye on Advancing Clinical Studies in 2022
- Lexaria Bioscience’s ongoing human clinical studies for its patented and trademarked DehydraTECH technology have yielded progressively optimistic results in 2021 regarding DehydraTECH’s ability to provide effective solutions for the cardiovascular industry
- DehydraTECH is being studied for its capacity to improve CBD’s ability to reduce high blood pressure in a rapid and sustainable manner that exceeds the ability of a generic CBD formulation
- DehydraTECH-CBD underwent three human clinical studies in 2021 that examined its ability to reduce arterial stiffness and blood pressure without creating unintended negative consequences
- A fourth, more comprehensive study was approved at year’s end, as the next step in the strategy, and dosing is tentatively expected to begin by April
Health and wellness drug bio-effectiveness innovator Lexaria Bioscience (NASDAQ: LEXX) is celebrating its multiple successes during 2021 after capping the year with regulatory approval for the most comprehensive study to date of its patented and trademarked technology as a potential treatment for hypertension.
Study protocols for HYPER-H21-4 were prepared as a continuation of 2021’s HYPER-H21-1 through HYPER-H21-3 studies that examined the capability of Lexaria’s DehydraTECH-CBD (cannabidiol)— to lower blood pressure, and to do so without adverse consequences.
Encouraging results from the first three studies have been reported during recent months, demonstrating DehydraTECH-CBD’s capacity to reduce arterial stiffness in mild-to-moderate hypertension (high blood pressure) volunteers, reduce their blood pressure, and function without creating adverse or unexpected consequences.
Lexaria classifies the human clinical studies as ongoing, and on Dec. 29 announced that an Independent Review Board (“IRB”) had approved the protocols for HYPER-H21-4, which is tentatively expected to begin dosing by April.
“Outcomes from this study could support Lexaria’s goals related to pursuit of regulatory approvals for DehydraTECH-CBD for potential use as a treatment for high blood pressure,” CEO Chris Bunka stated (https://nnw.fm/I9scG).
“Reducing arterial stiffness in Lexaria’s recent hypertension study after only a single day of dosing with our DehydraTECH-CBD is a major discovery,” Lexaria President John Docherty stated after follow-up results from HYPER-H21-2 were released last month (https://nnw.fm/roV7D). “We know that increased arterial stiffness is correlated with many serious and life-threatening diseases affecting people worldwide, and we are optimistic that our latest findings could have future widespread implications for promotion of improved human health and wellness.”
DehydraTECH helps certain drugs to be utilized more efficiently by the human body through an ingenious and patented new method of drug delivery that works more symbiotically with the human body than most previous technologies.
Establishing DehydraTECH’s ability to help treat high blood pressure in combination with CBD could serve as a springboard for treating other cardiovascular diseases as well. Arterial stiffness occurs naturally with age and is an indicated condition in the mortality rate from chronic diseases such as cardiovascular diseases and diabetes mellitus.
Clinical human study HYPER-H21-4 will also measure markers such as 24-hour ambulatory blood pressure (the primary outcome), blood biomarkers (including lipids such as cholesterol), sleep disorders and perceived stress, all of which have the potential to demonstrate DehydraTECH-CBD’s impact on chronic heart diseases beyond simple blood pressure responsiveness.
Lexaria’s Dec. 29 news release noted that there are several hypertension drugs that each generate $1 billion per year or more in revenue, and the company’s plans for HYPER-H21-4 are entirely funded through Lexaria’s existing cash resources and therefore will not be subject to any financing requirement, demonstrating the company’s efforts to be fiscally responsible in its pursuit of a marketable product solution for the cardiovascular industry.
For more information, visit the company’s website at www.LexariaBioscience.com.
NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://nnw.fm/LEXX
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
- Lexaria Bioscience’s ongoing human clinical studies for its patented and trademarked DehydraTECH technology have yielded progressively optimistic results in 2021 regarding DehydraTECH’s ability to provide effective solutions for the cardiovascular industry
- DehydraTECH is being studied for its capacity to improve CBD’s ability to reduce high blood pressure in a rapid and sustainable manner that exceeds the ability of a generic CBD formulation
- DehydraTECH-CBD underwent three human clinical studies in 2021 that examined its ability to reduce arterial stiffness and blood pressure without creating unintended negative consequences
- A fourth, more comprehensive study was approved at year’s end, as the next step in the strategy, and dosing is tentatively expected to begin by April
Health and wellness drug bio-effectiveness innovator Lexaria Bioscience (NASDAQ: LEXX) is celebrating its multiple successes during 2021 after capping the year with regulatory approval for the most comprehensive study to date of its patented and trademarked technology as a potential treatment for hypertension.
Study protocols for HYPER-H21-4 were prepared as a continuation of 2021’s HYPER-H21-1 through HYPER-H21-3 studies that examined the capability of Lexaria’s DehydraTECH-CBD (cannabidiol)— to lower blood pressure, and to do so without adverse consequences.
Encouraging results from the first three studies have been reported during recent months, demonstrating DehydraTECH-CBD’s capacity to reduce arterial stiffness in mild-to-moderate hypertension (high blood pressure) volunteers, reduce their blood pressure, and function without creating adverse or unexpected consequences.
Lexaria classifies the human clinical studies as ongoing, and on Dec. 29 announced that an Independent Review Board (“IRB”) had approved the protocols for HYPER-H21-4, which is tentatively expected to begin dosing by April.
“Outcomes from this study could support Lexaria’s goals related to pursuit of regulatory approvals for DehydraTECH-CBD for potential use as a treatment for high blood pressure,” CEO Chris Bunka stated (https://nnw.fm/I9scG).
“Reducing arterial stiffness in Lexaria’s recent hypertension study after only a single day of dosing with our DehydraTECH-CBD is a major discovery,” Lexaria President John Docherty stated after follow-up results from HYPER-H21-2 were released last month (https://nnw.fm/roV7D). “We know that increased arterial stiffness is correlated with many serious and life-threatening diseases affecting people worldwide, and we are optimistic that our latest findings could have future widespread implications for promotion of improved human health and wellness.”
DehydraTECH helps certain drugs to be utilized more efficiently by the human body through an ingenious and patented new method of drug delivery that works more symbiotically with the human body than most previous technologies.
Establishing DehydraTECH’s ability to help treat high blood pressure in combination with CBD could serve as a springboard for treating other cardiovascular diseases as well. Arterial stiffness occurs naturally with age and is an indicated condition in the mortality rate from chronic diseases such as cardiovascular diseases and diabetes mellitus.
Clinical human study HYPER-H21-4 will also measure markers such as 24-hour ambulatory blood pressure (the primary outcome), blood biomarkers (including lipids such as cholesterol), sleep disorders and perceived stress, all of which have the potential to demonstrate DehydraTECH-CBD’s impact on chronic heart diseases beyond simple blood pressure responsiveness.
Lexaria’s Dec. 29 news release noted that there are several hypertension drugs that each generate $1 billion per year or more in revenue, and the company’s plans for HYPER-H21-4 are entirely funded through Lexaria’s existing cash resources and therefore will not be subject to any financing requirement, demonstrating the company’s efforts to be fiscally responsible in its pursuit of a marketable product solution for the cardiovascular industry.
For more information, visit the company’s website at www.LexariaBioscience.com.
NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://nnw.fm/LEXX
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)Lexaria Bioscience Corp. (LEXX) Stock Research Links
Scroll down for more posts ▼